

TARGETED GENETICS CORP /WA/  
Form 8-K  
December 06, 2007

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **December 3, 2007**

**Targeted Genetics Corporation**  
(Exact name of registrant as specified in its charter)

**Washington**  
(State or other jurisdiction  
of incorporation)

**0-23930**  
(Commission File  
Number)

**91-1549568**  
(IRS Employer  
Identification No.)

**1100 Olive Way, Suite 100, Seattle, Washington**  
(Address of principal executive offices)

**98101**  
(Zip Code)

Registrant's telephone number, including area code

**(206) 623-7612**

**Not Applicable**

---

(Former name or former address if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-



**Item 8.01 Other Events.**

On December 3, 2007, Targeted Genetics Corporation announced the results of the National Institutes of Health Recombinant DNA Advisory Committee's assessment of the serious adverse event reported by the Company in its Phase I/II trial of tgAAC94 for inflammatory arthritis.

A copy of the press release issued in connection with this announcement is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits:

99.1 Press Release of Targeted Genetics Corporation dated December 3, 2007

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TARGETED GENETICS CORPORATION

Dated: December 6, 2007

By:

/s/ H. Stewart Parker

---

H. Stewart Parker  
President and Chief Executive Officer

**INDEX TO EXHIBITS**

99.1 Press Release of Targeted Genetics Corporation dated December 3, 2007